Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).

Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, Rodbard HW

Diabetes care11 Aug 2014Cited by 204 (Europe PMC)

PMID25114296DOI10.2337/dc14-0785PepBankPUB-25114296

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin and metformin, adding the liraglutide component (IDegLira versus insulin degludec alone) lowered A1C more over 26 weeks.
In plain wordsIn adults with type 2 diabetes, the combination containing liraglutide lowered A1C more than insulin degludec alone over 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseA1C change from baseline at 26 weeks
Study
n = 413
Comparator
Insulin degludec alone (plus metformin)
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg liraglutide (50 dose steps of IDegLira) · 26 weeksAs given in this study (human).
Measurements
A1C decrease
1.9%
IDegLira
A1C decrease
0.9%
insulin degludec
Estimated treatment difference
−1.1%
IDegLira vs insulin degludec
Source sentences
Summary
A1C decreased by 1.9% (21 mmol/mol) with IDegLira and by 0.9% (10 mmol/mol) with IDeg (estimated treatment difference -1.1% [95% CI -1.3, -0.8], -12 mmol/mol [95% CI -14, -9; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was change in A1C from baseline.
Summary · context
In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5-10.0% [58-86 mmol/mol]) on basal insulin (20-40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma gl…
Report a problemFND-2511429601
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the liraglutide-containing combination reduced weight by a mean of 2.7 kg, versus no weight change with insulin degludec alone.
In plain wordsIn adults with type 2 diabetes, the combination containing liraglutide reduced weight by 2.7 kg, while insulin degludec alone caused no weight change.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 413
Comparator
Insulin degludec alone (plus metformin)
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 1.8 mg liraglutide (50 dose steps of IDegLira) · 26 weeksAs given in this study (human).
Measurements
Mean weight reduction
2.7 kg
IDegLira
Source sentences
Summary
Mean weight reduction with IDegLira was 2.7 kg vs. no weight change with IDeg, P < 0.0001.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5-10.0% [58-86 mmol/mol]) on basal insulin (20-40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma gl…
Report a problemFND-2511429602
03HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, hypoglycemia incidence was comparable with the liraglutide-containing combination (24%) and insulin degludec alone (25%).
In plain wordsIn adults with type 2 diabetes, low blood sugar was about equally common with the liraglutide combination (24%) and insulin degludec alone (25%).
Peptide
Liraglutide
Outcome
No significant changeHypoglycemia incidence
Study
n = 413
Comparator
Insulin degludec alone (plus metformin)
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1.8 mg liraglutide (50 dose steps of IDegLira) · 26 weeksAs given in this study (human).
Measurements
Hypoglycemia incidence
24%
IDegLira
Hypoglycemia incidence
25%
insulin degludec
Source sentences
Summary
Hypoglycemia incidence was comparable (24% for IDegLira vs. 25% for IDeg).
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5-10.0% [58-86 mmol/mol]) on basal insulin (20-40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma gl…
Report a problemFND-2511429603
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, overall adverse events were similar between the liraglutide-containing combination and insulin degludec alone.
In plain wordsIn adults with type 2 diabetes, overall side effects were similar with the liraglutide combination and insulin degludec alone.
Peptide
Liraglutide
Outcome
No significant changeOverall adverse events
Study
n = 413
Comparator
Insulin degludec alone (plus metformin)
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1.8 mg liraglutide (50 dose steps of IDegLira) · 26 weeksAs given in this study (human).
Source sentences
Summary
Overall adverse events were similar
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5-10.0% [58-86 mmol/mol]) on basal insulin (20-40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma gl…
Report a problemFND-2511429604
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, nausea incidence was low in both groups (6.5% with the liraglutide-containing combination versus 3.5% with insulin degludec alone).
In plain wordsIn adults with type 2 diabetes, nausea was uncommon in both groups: 6.5% with the liraglutide combination and 3.5% with insulin degludec alone.
Peptide
Liraglutide
Outcome
No significant changeNausea incidence
Study
n = 413
Comparator
Insulin degludec alone (plus metformin)
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
up to 1.8 mg liraglutide (50 dose steps of IDegLira) · 26 weeksAs given in this study (human).
Measurements
Nausea incidence
6.5%
IDegLira
Nausea incidence
3.5%
insulin degludec
Source sentences
Summary
incidence of nausea was low in both groups (IDegLira 6.5% vs. IDeg 3.5%).
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5-10.0% [58-86 mmol/mol]) on basal insulin (20-40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma gl…
Report a problemFND-2511429605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01392573

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 41328 Nov 2011 to 4 Oct 2012

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 3 Jan 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.